CERO (CERo Therapeutics Holdings) Current Accrued Expense: $0.26 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CERo Therapeutics Holdings Current Accrued Expense?

CERo Therapeutics Holdings CERO -0.79% Current Accrued Expense is $0.26 Mil as of Jun. 2026. The stock has 2 warning signs investors should review.

CERo Therapeutics Holdings's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.26 Mil.

CERo Therapeutics Holdings's quarterly Current Accrued Expense increased from Dec. 2025 ($0.12 Mil) to Mar. 2026 ($0.27 Mil) but then declined from Mar. 2026 ($0.27 Mil) to Jun. 2026 ($0.26 Mil).

CERo Therapeutics Holdings's annual Current Accrued Expense increased from Dec. 2023 ($0.08 Mil) to Dec. 2024 ($1.59 Mil) but then declined from Dec. 2024 ($1.59 Mil) to Dec. 2025 ($0.12 Mil).

CERo Therapeutics Holdings Current Accrued Expense Related Terms

CERo Therapeutics Holdings Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for CERo Therapeutics Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings Current Accrued Expense Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.03 0.08 0.08 1.59 0.12

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.26 0.12 0.27 0.26

CERo Therapeutics Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.26 Mil mean?
CERo Therapeutics Holdings (CERO) has a Current Accrued Expense of $0.26 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on CERo Therapeutics Holdings and its competitors.
Is CERo Therapeutics Holdings' Current Accrued Expense too high?
CERo Therapeutics Holdings' current Current Accrued Expense is $0.26 Mil.
How does CERo Therapeutics Holdings' Current Accrued Expense compare to AGTX and ZVSA?
CERo Therapeutics Holdings' Current Accrued Expense of $0.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on CERo Therapeutics Holdings and its competitors. CERo Therapeutics Holdings's current Current Accrued Expense is $0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current Current Accrued Expense of $0.26 Mil. The current Current Accrued Expense is $0.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current Current Accrued Expense is $0.26 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CERo Therapeutics Holdings Business Description

Address 201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.